RecruitingNCT06321679

Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone

Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone: A Whole Body MRI Study

Sponsor

European Institute of Oncology

Enrollment

40 participants

Start Date

Jul 3, 2020

Study Type

OBSERVATIONAL

Conditions

Castration-resistant Prostate Cancer

Summary

This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.

Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria5

Histological diagnosis of castration-resistant prostate cancer,
Single or multiple bone metastases,
Life expectancy of over 6 months,
No current active malignancy other than prostate cancer,
Provision of written informed consent.

Exclusion Criteria3

Absolute contraindication to WB-MRI, CT or BS,
Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion),
Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.